November 2 (Mon)

Transcription

November 2 (Mon)

A = Student Award
November 2 (Mon)
Seiun Room 1 (The Westin Nagoya Castle 2F)
14:30 - 15:00 Opening Remarks and Announcements
Hiroyuki Tsuda (Japan)
15:00 - 15:40 Plenary Lecture 1
Chair: Hiroyuki Tsuda (Japan)
PL-1
15:00 - 15:40
Lactoferrin and its receptor – physiological implications
Bo Lönnerdal (USA)
Chair: Hiroyuki Tsuda (Japan)
PL-2
15:40 - 16:20
Molecular mechanism of lactoferrin in neurodevelopment and cognitive function
Bing Wang (Australia)
16:20 - 16:40 Coffee Break
Chair: Bo Lönnerdal (USA)
PL-3
16:40 - 17:20
Lactoferrin (LF) acts as an adjuvant in influenza vaccination of immature newborn
mice
Michael Sherman (USA)
PL-4
17:20 - 18:00
Evolving views of the functions and applications of lactoferrin, and the importance
of its molecular structure
Edward N. Baker (New Zealand)
14
18:10 - 19:00 Poster Session 1 “Student Awardee Poster Session”
Chair: Katsufumi Otsuki (Japan)
P-01 A
A new model for the interaction between lactoferrin binding protein B and lactoferrin
P-02 A
Effects of bovine lactoferrin on facial pathological pain following a trigeminal nerve
injury
Nicholas Kane Hunter Ostan (Canada)
Kayo Horie (Japan)
P-03 A
Promoting effect of bovine lactoferrin on epithelial differentiation and barrier
function of HaCaT human keratinocytes
Ryo Uchida (Japan)
P-04 A
Lactoferrin and LF-derived synthetic peptides decrease fimbrial gene expression and
suppress the adherence of Enteroaggregative Escherichia coli to HEp-2 cells in vitro
Jorge E. Valdez-Flores (Mexico)
P-05 A
Effect of lactoferrin and lactoferrin-derived synthetic peptides on Streptococcus
pneumoniae biofilms and its impact in the Quorum Sensing System
Uriel A. Angulo-Zamudio (Mexico)
P-06 A
Regulation of iron metabolism and inflammation by supplemental lactoferrin (Lf) in
pre-weanling lactoferrin receptor (LfR) knockout mice
Lauren Roukia Brink (USA)
P-07 A
Effects of lactoferrin on blood glucose level and glucose absorption in the small intestine
P-08 A
Structure of tryptically produced iron-free C-lobe of lactoferrin and its functional
significance in the gut
Yuta Maekawa (Japan)
Nilisha Rastogi (India)
15
November 3 (Tue)
Seiun Room1 (The Westin Nagoya Castle 2F)
9:00 - 10:35
Oral Session 1 “Aspects of LF Research 1”
Chairs: Edward N. Baker (New Zealand)
Mamoru Tomita (Japan)
L-1
9:00 - 9:35
Research & development on lactoferrin and its derivates in China during 2011-2015
L-2
9:35 - 10:10
The role of lactoferrin binding protein B
O-01 A
10:10 - 10:35
A new model for the interaction between lactoferrin binding protein B and lactoferrin
Jianhua Wang (China)
Anthony Bernard Schryvers (Canada)
Nicholas Kane Hunter Ostan (Canada)
10:50 - 12:25 Oral Session 2 “Aspects of LF Research 2”
Chairs: Anthony Bernard Schryvers (Canada)
Yasushi Suzuki (Japan)
L-3
10:50 - 11:25
Crosstalk between posttranslational modifications regulates delta-lactoferrin
antitumoral activities
L-4
11:25 - 12:00
A new role for lactoferrin: The protection of the developing brain ?
O-02
12:00 - 12:25
FC domain of IgG conjugated lactoferrin shows an enhancement of antinociception
after continuous infusion into jugular vein in rat
Annick Pierce (France)
Stephane Sizonenko (Switzerland)
Takashi Takeuchi (Japan)
12:25 - 13:15 Lunch
13:15 - 14:40 Oral Session 3 “Immune Modulation”
Chairs: Jean-Paul Perraudin (Belgium)
Annick Pierce (France)
O-03
13:15 - 13:50
Lactoferrin as an immune modulatory therapy for tuberculosis disease
O-04
13:50 - 14:15
Lactoferrin modulates “Immunothrombosis” in inflammatory diseases
O-05
14:15 - 14:40
Oral supplementation of bovine lactoferrin and lactoferrin-hydrolysate attenuates
skin damage in UVB-irradiated hairless mice
Shen-An Hwang (USA)
Junichi Hirahashi (Japan)
Mai Murata (Japan)
16
14:55 - 16:20 Oral Session 4 “Antimicrobial/antiviral activity 1”
Chairs: Piera Valenti (Italy)
Hidefumi Kuwata (Japan)
L-5
14:55 - 15:30
Parasiticidal effect of bovine Lactoferrin-derived synthetic peptides on the enteric
parasite Giardia intestinalis
O-06 A
15:30 - 15:55
Lactoferrin and LF-derived synthetic peptides decrease fimbrial gene expression
and suppress the adherence of Enteroaggregative Escherichia coli to HEp-2 cells
Nidia León-Sicairos (Mexico
in vitro
Jorge E. Valdez-Flores (Mexico)
O-07 A
15:55 - 16:20
Effect of lactoferrin and lactoferrin-derived synthetic peptides on Streptococcus
pneumoniae biofilms and its impact in the Quorum Sensing System
Uriel A. Angulo-Zamudio (Mexico)
16:35 - 18:25 Oral Session 5 “Antimicrobial/antiviral activity 2”
Chairs: Nidia León-Sicairos (Mexico)
Yukimichi Tamaki (Japan)
L-6
16:35 - 17:10
Aerosolized lactoferrin reduces inflammation and infection in a mouse model of
cystic fibrosis lung infection
O-08
17:10 - 17:35
Efficacy of lactoferrin in patients with refractory bacterial vaginosis
O-09 A
17:35 - 18:00
Effects of lactoferrin and lactoperoxidase-containing tablets on oral hygiene status
O-10
18:00 - 18:25
A randomized, double-blind, crossover, placebo-controlled clinical trial to assess
effects of a tablet containing lactoferrin and lactoperoxidase on oral malodor
Piera Valenti (Italy)
Katsufumi Otsuki (Japan)
Yu Morita (Japan)
Manabu Nakano (Japan)
17
18:40 - 19:30 Poster Session 2
Chairs: Katsuaki Tanaka (Japan)
Reeko Sato (Japan)
P-09
Research & development on lactoferrin and its derivates in China during 2011-2015
P-10
Glycated lactoferrin induces activation of TLR2 and TLR4 in CD14+ cells of human
peripheral blood macrophages
Jianhua Wang (China)
Lopez Soto Fernando (Mexico)
P-11
Lactoferrin potentiates differentiation of regulatory T cells
P-12
Oral administration of liposomal bovine lactoferrin suppresses progression of
rheumatoid arthritis
Sun-jin Kim (Korea)
Shunryo Yanagisawa (Japan)
P-13
Hepatoprotective effect of lactoferrin against tumor necrosis factor-alpha related
experimental hepatic failure
Katsuaki Tanaka (Japan)
P-14
Oral administration of lactoferrin protects dimethylnitrosamine1-induced chemical
injury of liver fibrosis in animal model
Chuan-mu Chen (Taiwan)
P-15
Aerosolized bovine lactoferrin prevents hyperoxia-induced chronic lung injury and
fibrosis in mouce animal model
Hsiao-ling Chen (Taiwan)
P-16
Lactoferrin is the effective for reduction of the oxidative stress
P-17
Development of experimental pastes including lactoferrin for oral mucosa disease
Yu Kataoka (Korea)
Yukimichi Tamaki (Korea)
18
November 4 (Wed)
9:00 - 10:25
Workshop 1
Chairs: Kei-ichi Shimazaki (Japan)
Theresa Jean Ochoa (Peru)
W-1
9:00 - 9:35
Potential anti-norovirus activity of lactoferrin and its peptides
W-2
9:35 - 10:00
Effects of lactoferrin on the production of interferon lambda by the human
intestinal epithelial cell line, HT-29
W-3
10:00 - 10:25
Potent anti-obesity effect of enteric-coated lactoferrin: Decrease in visceral
fat accumulation in Japanese men and women with abdominal obesity and
its possible mechanisms
Hirotsugu Oda (Japan)
Kouichirou Shin (Japan)
Satoru Morishita (Japan)
10:40 - 12:20 Workshop 2
Chairs: Takashi Takata (Japan)
Takashi Takeuchi (Japan)
W-4
10:40 - 11:05
The preventive effect of lactoferrin on hypercholesterolemia; LF increases
fecal cholesterol excretion by reducing micellar solubility of cholesterol
W-5 A
11:05 - 11:30
Effects of lactoferrin on blood glucose level and glucose absorption in the small
intestine
W-6
11:30 - 11:55
Expansion of enteric technology for more versatile oral delivery of lactoferrin:
Development of novel microcapsulized lactoferrin and its effect on NASH-HCC
model mice
Kanae Nakamura (Japan)
Yuta Maekawa (Japan)
Hidefumi Kuwata (Japan)
W-7
11:55 - 12:20
Development of a powdered beverage containing enteric-coated lactoferrin for
the prevention of non-alcoholic steatohepatitis (NASH)
Motoki Tatsumi (Japan)
12:20 - 13:10 Lunch
19
November 5 (Thu)
9:00 - 10:10
Oral Session 6 “Antimicrobial/antiviral activity 3”
Chairs: Hans J. Vogel (Canada)
Koji Yamauchi (Japan)
L-7
9:00 - 9:35
Role of lactoferrin on inflammation and iron homeostasis in Chlamydia
trachomatis infection
O-11
9:35 - 10:10
Randomized controlled trial of lactoferrin for prevention of sepsis in neonates
< 2000g
Piera Valenti (Italy)
10:25 - 12:15 Oral Session 7 “Antimicrobial/antiviral/anticancer”
Chairs: Jianhua Wang (China)
Yoshiharu Takayama (Japan)
L-8
10:25 - 11:00
Lactoferrin and its host defense peptides: antimicrobial, antibiofilm and
anticancer effects
O-12
11:00 - 11:25
Anti-tumor effects on lymphoma cells expressing HTLV-1 Tax and inhibition
of HTLV-1 cell-to-cell spread by bovine lactoferrin
O-13
11:25 - 11:50
Anti-melanogenic effect of bovine lactoferrin: molecular requirement and
mechanism
O-14
11:50 - 12:15
Bovine Lactoferrin specifically inhibits tumor angiogenesis
Hans J. Vogel (Canada)
Masakazu Tanaka (Japan)
Nanase Ishii (Japan)
Takashi Takata (Japan)
12:15 - 13:05 Lunch
20
13:05 - 14:55 Oral Session 8 “LF in the intestine”
O-15 A
13:05 - 13:40
Regulation of iron metabolism and inflammation by supplemental lactoferrin (Lf)
in pre-weanling lactoferrin receptor (LfR) knockout mice
O-16
13:40 - 14:05
CXC Chemokine Receptor 4 (CXCR4) behaves as a lactoferrin receptor
O-17
14:05 - 14:30
Time-lapse analysis of lactoferrin-uptake mechanisms into intestinal epithelial cells
O-18
14:30 - 14:55
Lactoferrin meets the neonatal intensive care habitat: The fecal microbiome
composition and reduced infections infants
Lauren Roukia Brink (USA)
Yoshiharu Takayama (Japan)
Asuka Nagae (Japan)
Michael P. Sherman (USA)
15:10 - 17:15 Oral Session 9 “Milk, formula, Ingested LF”
Chairs: Nidia León-Sicairos (Mexico)
Michiaki Murakoshi (Japan)
O-19
15:10 - 15:35
A comparison of analytical methods for measuring lactoferrin in dairy products
O-20
15:35 - 16:00
Lactoferrin researches in infants and usage as infant formula for 30 years
O-21
16:00 - 16:25
Factors associated with lactoferrin concentration in breast milk of Peruvian
mothers of low-birth-weight infants
O-22
16:25 - 16:50
Impact of oral ingestion of bovine lactoferrin on peptidome in human blood
O-23 A
16:50 - 17:15
Structure of tryptically produced iron-free C-lobe of lactoferrin and its functional
significance in the gut
Jaganmohan Billakanti (New Zealand)
Hiroyuki Wakabayashi (Japan
Kenji Sato (Japan
Nilisha Rastogi (India)
21
Chair: Hiroyuki Wakabayashi (Japan)
P-18
Design and antimicrobial activity of bovine lactoferricin-derived synthetic peptides
P-19
Antimicrobial effect of bovine lactoferrin synthetic derived peptides and the
internalization in Enteroagregative Escherichia coli
Xiumin Wang (China)
Adrian Canizalez-Roman (Mexico)
P-20
Prophylactic and therapeutic effect of Lactoferrin and Lactoferrin chimera in
a mouse model of intestinal Vibrio cholerae infection
Jorge A. Velazquez-Roman (Mexico)
P-21
Effects of lactoferrin on the viability and the encystment of Acanthamoeba
trophozoites
Shinichi Tomita (Japan)
P-22
Lactoferrin and lactoferrin hydrolysate inhibit propagation of murine norovirus
in RAW264.7 cells
Hirotsugu Oda (Japan)
P-23
Anti-tumor effects on lymphoma cells expressing HTLV-1 Tax and inhibition of
HTLV-1 cell-to-cell spread by bovine lactoferrin
Masakazu Tanaka (Japan)
P-24
Bovine lactoferrin attenuates growth and bone invasion of oral squamous cell
carcinoma
Chea Chanbora (Japan)
P-25
Bioactive peptides released by gastrointestinal digestion of human milk and
infant formula in suckling rat pups
Yasuaki Wada (Japan)
Chair: Satoru Morishita (Japan)
P-26
Lactoferrin and retinoic acid synergize to enhance intestinal IgA response
P-27
The preventive effect of lactoferrin-containing yogurt on infectious diseases in
children -15 weeks intervention study-
Hyeon-jin Kim (Korea)
Anri Fujimori (Japan)
P-28
Development of a novel immuno-enhancing formula containing bovine lactoferrin
P-29
Protein-surfactant interactions between bovine lactoferrin and sophorolipids
under neutral and acidic conditions
Namiko Seto (Japan)
Kentaro Matsumiya (Japan)
P-30
Advances in lactoferrin research in studies on bovine mastitis
Kei-ichi Shimazaki (Japan)
22
P-31
Immunostimulation of Bovine Lactoferrin (bLF) on cattle infected with mastitis
and its application to clinical mastitis cases
Masashi Itagaki (Japan)
P-32
Effect of Vitreoscilla hemoglobin expression on the cell growth and human
lactoferrin (hLf) production in recombinant Pichia pastoris displaying hLf on
the cell surface
Hyune Hwan Lee (Korea)
P-33
Are lactoferrin products well accepted by final consumers?
The Spanish market as study case
Pilar Mier (Spain)
P-34
Preparation of Lactoferrin N-lobe and C-lobe Models by 3D-Printer
Kei-ichi Shimazaki (Japan)
23
November 6 (Fri)
9:00 - 10:15
Oral Session 10 “Novel functions and applications of lactoferrin 1”
Chair: Kei-ichi Shimazaki (Japan)
O-24
9:00 - 9:25
Lactoferrin protects against rhabdomyolysis-induced acute kidney injury
O-25
9:25 - 9:50
Bovine lactoferrin and Crohn's Disease: A case report
O-26
9:50 - 10:15
Hinge-deficient human lactoferrin-Fc fusion protein as a potential therapeutic agent
Koshu Okubo (Japan)
David B. Alexander (Japan)
Yuki Shiga (Japan)
10:30 - 11:20 Oral Session 11 “Novel functions and applications of lactoferrin 2”
Chair: Anthony Bernard Schryvers (Canada)
O-27
10:30 - 10:55
Direct evidence of nitric oxide production in bovine lactoferrin-induced
hypotension and enhancing effect of magnesium on this production
O-28 A
10:55 - 11:20
Promoting effect of bovine lactoferrin on epithelial differentiation and barrier
function of HaCaT human keratinocytes
Atsushi Miyamoto (Japan)
Ryo Uchida (Japan)
11:20 - 11:45 Excellent Student Award and Genevieve Spik Award Ceremony
11:45 - 11:50 Concluding Remarks
11:50 - 12:40 Lunch
24

November 2 (Mon)

Transcription

Similar documents